Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Recurrence 1Lethal Congenital Contracture Syndrome 2 1Fibromatosis, Gingival, 2 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × patritumab × Clear all
NCT02350712 2018-09-11

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Daiichi Sankyo

Phase 1 Completed
15 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT01957280 2014-05-14

Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)

Daiichi Sankyo

Phase 1 Completed
17 enrolled
Other solid neoplasm

Solid Tumors

NCT00730470 2010-07-29

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

U3 Pharma GmbH

Phase 1 Completed
60 enrolled

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡